Today, we announced our Q2 2025 financial results and provided company updates. Details: https://lnkd.in/emxxz-PY
Aurinia Pharmaceuticals Inc.
Biotechnology Research
Edmonton, Alberta 27,142 followers
About us
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 2. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. 3. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. 4. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: https://www.auriniapharma.com/aurinia-community-guidelines US-NA-2300266 08/23
- Website
-
http://www.auriniapharma.com/
External link for Aurinia Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Edmonton, Alberta
- Type
- Public Company
- Founded
- 2013
- Specialties
- Biotechnology, Immunology, Lupus Nephritis, Drug Development, autoimmune, Nephrology, and Rheumatology
Locations
-
Primary
Get directions
Edmonton, Alberta, CA
-
Get directions
#201, 17904 - 105 Avenue
Edmonton (West Northwest Industrial / Winterburn), AB T5S 2H5, CA
-
Get directions
77 Upper Rock Circle
Suite 700
Rockville, MD 20850 , US
Employees at Aurinia Pharmaceuticals Inc.
Updates
-
This year’s EULAR - European Alliance of Associations for Rheumatology 2025 meeting will feature presentations from Aurinia Pharmaceuticals, including new data on deep proteinuria reduction in patients with #LupusNephritis. Read more: https://lnkd.in/e_4SeKP4
-
-
Happy #PrideMonth! We believe innovation comes from a multitude of perspectives, so we’re committed to fostering a diverse and inclusive environment where every employee can thrive. Join us as we celebrate the LGBTQIA+ community all year long here at Aurinia.
-
-
At Aurinia, we're passionate about putting #LNinFocus, especially during #LupusAwarenessMonth. Our team is helping advance our mission to change the trajectory of autoimmune diseases.
-
-
We’re proud to celebrate Tom Buettner and Federico Camacho as recipients of Aurinia’s Influencer Awards! Tom Buettner, Associate Director of Supply Chain and Logistics, was recognized for going above and beyond to embody Aurinia Values, especially “Collaborate and Achieve Together.” Federico Camacho, Quality Assurance Manager, was recognized for his dedication and commitment through his embodiment of the Aurinia Values “Collaborate, Achieve Together, and Act Responsibly.” Congratulations to Tom and Frederico! #EmployeeRecognition #TeamAurinia
-
-
At this year’s #LUPUS2025, Aurinia Pharmaceuticals will be presenting new research on innovative approaches to reduce proteinuria in patients with #lupusnephritis. https://lnkd.in/euqwRpMc
-
-
Many lupus symptoms can be obvious. But when it comes to the kidneys, some of the signs can be easy to overlook. #LupusNephritis (LN) may progress without flares, pain, or visible warning. But if you’re testing for it, the signal may be there. This #LupusAwarenessMonth, don’t wait for symptoms to show. Make #TheKidneyCheck part of your lupus protocol. #LNinFocus
-
Lupus Nephritis (LN) is the most serious complication of lupus, and symptoms can be subtle but severe, damaging kidneys without obvious symptoms. To put #LNinFocus, we are introducing #TheKidneyCheck: A straightforward, three-part checklist to standardize essential screening during every lupus workup. Implementing routine checks paves the way for timely treatment and long-term protection against LN. Putting #LNinFocus elevates the standard of lupus care this #LupusAwarenessMonth and beyond.
-
We are excited to share the publication of our AURORA 2 biopsy sub-study in American College of Rheumatology's Arthritis & Rheumatology Journal. We encourage rheumatology healthcare professionals to learn more about these findings here: https://lnkd.in/efRDEjYm
-
-
Today, we announced our Q1 2025 financial results and provided company updates. Details: https://lnkd.in/eX4VzAHv
-